Andrew Willmore
Overview
Explore the profile of Andrew Willmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bogart A, Lopez C, Obeidalla S, Wang C, Willmore A, Jauregui A, et al.
CHEST Crit Care
. 2024 Oct;
2(3).
PMID: 39421542
Background: Only a subset of patients at risk for ARDS go on to develop it, and the contribution of preexisting comorbidities (eg, diabetes) to ARDS risk is not well understood....
2.
Neyton L, Patel R, Sarma A, Willmore A, Haller S, Kangelaris K, et al.
Nat Commun
. 2024 Jun;
15(1):5483.
PMID: 38942804
Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood....
3.
Evrard B, Sinha P, Delucchi K, Hendrickson C, Kangelaris K, Liu K, et al.
Crit Care
. 2024 May;
28(1):164.
PMID: 38745253
Background: Hypoinflammatory and hyperinflammatory phenotypes have been identified in both Acute Respiratory Distress Syndrome (ARDS) and sepsis. Attributable mortality of ARDS in each phenotype of sepsis is yet to be...
4.
Valda Toro P, Willmore A, Wu N, Delucchi K, Jauregui A, Sinha P, et al.
Crit Care
. 2024 Apr;
28(1):132.
PMID: 38649920
Background: Rapidly improving acute respiratory distress syndrome (RIARDS) is an increasingly appreciated subgroup of ARDS in which hypoxemia improves within 24 h after initiation of mechanical ventilation. Detailed clinical and...
5.
Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, et al.
Crit Care
. 2024 Feb;
28(1):56.
PMID: 38383504
Background: Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity...
6.
Sinha P, Kerchberger V, Willmore A, Chambers J, Zhuo H, Abbott J, et al.
Lancet Respir Med
. 2023 Aug;
11(11):965-974.
PMID: 37633303
Background: In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular phenotypes (hypoinflammatory and hyperinflammatory) have consistently been identified, with...
7.
Neyton L, Patel R, Sarma A, Willmore A, Haller S, Kangelaris K, et al.
Res Sq
. 2023 Aug;
PMID: 37577607
Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood....
8.
Alipanah-Lechner N, Neyton L, Mick E, Willmore A, Leligdowicz A, Contrepois K, et al.
Am J Physiol Lung Cell Mol Physiol
. 2023 Jan;
324(3):L297-L306.
PMID: 36648136
Using latent class analysis (LCA) of clinical and protein biomarkers, researchers have identified two phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and treatment responses. We...
9.
Wick K, Leligdowicz A, Willmore A, Carrillo S, Ghale R, Jauregui A, et al.
Crit Care
. 2022 Sep;
26(1):278.
PMID: 36104754
Background: Studies quantifying SARS-CoV-2 have focused on upper respiratory tract or plasma viral RNA with inconsistent association with clinical outcomes. The association between plasma viral antigen levels and clinical outcomes...
10.
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard P, Vazquez S, Liu J, Laurie M, Wang C, Gervais A, et al.
Sci Immunol
. 2022 Jul;
8(90):eabp8966.
PMID: 35857576
Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie...